Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The ...

B. Riley upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on ...